PurposeThe aim of this study was to examine the physical and training characteristics of recreational marathon runners within finish time bandings (2.5–3 h, 3–3.5 h, 3.5–4 h, 4–4.5 h and >4.5 h).Materials and methodsA total of 97 recreational marathon runners (age 42.4 ± 9.9 years; mass 69.2 ± 11.3 kg; stature 172.8 ± 9.1 cm), with a marathon finish time of 229.1 ± 48.7 min, of whom n = 34 were female and n = 63 were male, completed an incremental treadmill test for the determination of lactate threshold (LT1), lactate turn point (LT2) and running economy (RE). Following a 7-min recovery, they completed a test to volitional exhaustion starting at LT2 for the assessment of trueV˙normalO2max. In addition, all participants completed a questionnaire gathering information on their current training regimes exploring weekly distances, training frequencies, types of sessions, longest run in a week, with estimations of training speed, and load and volume derived from these data.ResultsTraining frequency was shown to be significantly greater for the 2.5–3 h group compared to the 3.5–4 h runners (P < 0.001) and >4.5 h group (P = 0.004), while distance per session (km·session−1) was significantly greater for the 2.5–3 h group (16.1 ± 4.2) compared to the 3.5–4 h group (15.5 ± 5.2; P = 0.01) and >4.5 h group (10.3 ± 2.6; P = 0.001). Race speed correlated with LT1 (r = 0.791), LT2 (r = 0.721) and distance per session (r = 0.563).ConclusionThe data highlight profound differences for key components of marathon running (trueV˙normalO2max, LT1, LT2, RE and % trueV˙normalO2max) within a group of recreational runners with the discriminating training variables being training frequency and the absolute training speed.

The purpose of this study was to examine the effect of menstrual cycle phase on maximal oxygen uptake (V˙O2max) and associated cardiodynamic responses. A total of 16 active females volunteered of which n = 10 formed the non-oral contraceptive pill group (n-OCP), displaying a regular menstrual cycle of 28·4 ± 2·2 days (age 20·6 ± 1·6 years, height 169·9 ± 6·4 cm, mass 68·7 ± 7·9 kg) and n = 6 formed the oral contraceptive pill group (OCP) (monophasic pill) (age 21·7 years ± 2·16, height 168·1 cm ± 6·8 cm, mass 61·6 ± 6·8 kg). Each completed four incremental exercise tests for determination of V˙O2max, cardiac output, stroke volume and heart rate. Each test was completed according to the phases of the menstrual cycle as determined through salivary analysis of 17-β oestrodiol and progesterone. Non-significant differences were observed for V˙O2max across phases and between groups (P>0·05) with additional non-significant differences for Q˙max, HR and SV between groups. For ∆ V˙O2 during the final 60 s of the V˙O2max trial, significant differences were observed between OCP and n-OCP (P<0·05) with OCP showing zero V˙O2 plateaus in three pseudo-phases. Significant difference observed for a-vO n-OCP between premenstruation and menstruation at 30-100% V˙O2max (P<0·05). Data suggest that the V˙O2 -plateau is effected by monophasic oral contraceptive pill, furthermore these data imply that V˙O2max test outcome is independent of menstrual cycle phase but caution should be applied when evaluating maximal oxygen uptake in females who are administered a monophasic oral contraceptive pill.

No abstract

These data suggest that plateau at VO2max is unaffected by O2 availability lending support to the notion of the plateau being dependent on the anaerobic capacity and the classically orientated concept of VO2max.

Short-term energy deficit strategies are practiced by weight class and physique athletes, often involving high protein intakes to maximize satiety and maintain lean mass despite a paucity of research. This study compared the satiating effect of two protein diets on resistance-trained individuals during short-term energy deficit. Following ethical approval, 16 participants (age: 28 ± 2 years; height: 1.72 ± 0.03 m; body-mass: 88.83 ± 5.54 kg; body-fat: 21.85 ± 1.82%) were randomly assigned to 7-days moderate (PROMOD: 1.8 g·kg−1·d−1) or high protein (PROHIGH: 2.9 g·kg−1·d−1) matched calorie-deficit diets in a cross-over design. Daily satiety responses were recorded throughout interventions. Pre-post diet, plasma ghrelin and peptide tyrosine tyrosine (PYY), and satiety ratings were assessed in response to a protein-rich meal. Only perceived satisfaction was significantly greater following PROHIGH (67.29 ± 4.28 v 58.96 ± 4.51 mm, p = 0.04). Perceived cravings increased following PROMOD only (46.25 ± 4.96 to 57.60 ± 4.41 mm, p = 0.01). Absolute ghrelin concentration significantly reduced post-meal following PROMOD (972.8 ± 130.4 to 613.6 ± 114.3 pg·mL−1; p = 0.003), remaining lower than PROHIGH at 2 h (−0.40 ± 0.06 v −0.26 ± 0.06 pg·mL−1 normalized relative change; p = 0.015). Absolute PYY concentration increased to a similar extent post-meal (PROMOD: 84.9 ± 8.9 to 147.1 ± 11.9 pg·mL−1, PROHIGH: 100.6 ± 9.5 to 143.3 ± 12.0 pg·mL−1; p < 0.001), but expressed as relative change difference was significantly greater for PROMOD at 2 h (+0.39 ± 0.20 pg·mL−1 v −0.28 ± 0.12 pg·mL−1; p = 0.001). Perceived hunger, fullness and satisfaction post-meal were comparable between diets (p > 0.05). However, desire to eat remained significantly blunted for PROMOD (p = 0.048). PROHIGH does not confer additional satiating benefits in resistance-trained individuals during short-term energy deficit. Ghrelin and PYY responses to a test-meal support the contention that satiety was maintained following PROMOD, although athletes experiencing negative symptoms (i.e., cravings) may benefit from protein-rich meals as opposed to over-consumption of protein.